Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

VIVianca Ibarra-GarciaMCMaría Eréndira Calleja-CervantesRMRebeca Martínez-Turrillas

Discussion

Loading...

Member takes

Overview

Innovative sdAb CAR-T cells improve survival and therapeutic efficacy in multiple myeloma, indicating advancement over existing treatments.

Key Points

  • To develop and evaluate sdAb-based CAR-T cells targeting BCMA for improved treatment of multiple myeloma.
  • Developed sdAb-based CAR-T cells targeting BCMA using phage display libraries from immunized llamas.
  • Evaluated binding kinetics and affinity using surface plasmon resonance and ELISA.
  • Assessed functional performance in vitro using Jurkat reporter systems and in vivo in NSG mice xenograft models.
  • sdAb-based CAR-T cells showed enhanced antitumoral efficacy and improved survival rates compared to idebacel.
  • sdAb5 exhibited similar initial efficacy to cilta-cel but superior long-term persistence and tumor control.
  • Flow cytometry revealed enrichment of memory-like CAR-T cells with sustained IL-2 production and a favorable immune profile.

Cite This Study

Ibarra-Garcia et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da8ehttps://doi.org/10.1182/blood-2025-4072
View Full Paper
Ask AI
Bookmark
Share